Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 0.98 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.98 |
| ▸ | GAK | O14976 | 3/20 | 0.96 |
| ▸ | ILK | Q13418 | 3/20 | 0.96 |
| ▸ | KDR | P35968 | 2/20 | 0.96 |
| ▸ | PLK4 | O00444 | 1/20 | 0.96 |
| ▸ | CIT | O14578 | 1/20 | 0.96 |
| ▸ | AURKA | O14965 | 1/20 | 0.96 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.96 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.96 |
| ▸ | BUB1 | O43683 | 1/20 | 0.96 |
| ▸ | KDM1A | O60341 | 1/20 | 0.96 |
| ▸ | JAK2 | O60674 | 1/20 | 0.96 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.96 |
| ▸ | STK17B | O94768 | 1/20 | 0.96 |
| ▸ | STK10 | O94804 | 1/20 | 0.96 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL1759094 | 1.00 | EGFR (0.98) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL417841 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL29460839 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL18563 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL21176918 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL16767632 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL29351329 | 0.98 | EGFR (1.00) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL30362833 | 0.98 | EGFR (1.00) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL3667407 | 0.98 | EGFR (1.00) | EGFRERBB2GAKILKKDR | |
| Erlotinib SCHEMBL8413 | 0.98 | EGFR (1.00) | EGFRERBB2GAKILKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749048-A | A kind of Eriotinib Hydrochloride form compound and preparation method thereof | 山东裕欣药业有限公司 | 2017-05-31 | — | — | CN | claimed |
| US-8372856-B2 | Crystalline, formed by crystallizing from an aqueous solution without agitation; treating cancer | SYNTHON BV (NL) | 2013-02-12 | — | — | US | claimed |
| EP-2099772-A2 | HYDRATES OF ERLOTINIB HYDROCHLORIDE | Synthon B.V. (NL) | 2009-09-16 | — | — | EP | claimed |
| US-20080167327-A1 | Crystalline, formed by crystallizing from an aqueous solution without agitation; treating cancer | SYNTHON BV (NL) | 2008-07-10 | — | — | US | claimed |
| WO-2008049645-A2 | HYDRATES OF ERLOTINIB HYDROCHLORIDE | SYNTHON B.V. (NL) | 2008-05-02 | — | — | WO | claimed |
| CN-106749048-B | Erlotinib hydrochloride crystal form compound and preparation method thereof | 山东裕欣药业有限公司 | 2020-03-20 | — | — | CN | disclosed |
| CN-106749048-A | A kind of Eriotinib Hydrochloride form compound and preparation method thereof | 山东裕欣药业有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-103124557-A | Pure erlotinib | GENERICS UK LTD | 2013-05-29 | — | — | CN | disclosed |
| US-8372856-B2 | Crystalline, formed by crystallizing from an aqueous solution without agitation; treating cancer | SYNTHON BV (NL) | 2013-02-12 | — | — | US | disclosed |
| US-8372856-B2 | Crystalline, formed by crystallizing from an aqueous solution without agitation; treating cancer | SYNTHON BV (NL) | 2013-02-12 | — | — | US | disclosed |
| US-7625911-B2 | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion | MAI DE LTD. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2099772-A2 | HYDRATES OF ERLOTINIB HYDROCHLORIDE | Synthon B.V. (NL) | 2009-09-16 | — | — | EP | disclosed |
| EP-2099772-A2 | HYDRATES OF ERLOTINIB HYDROCHLORIDE | Synthon B.V. (NL) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008049645-A3 | HYDRATES OF ERLOTINIB HYDROCHLORIDE | SYNTHON BV (NL) | 2008-07-31 | — | — | WO | disclosed |
| US-20080167327-A1 | Crystalline, formed by crystallizing from an aqueous solution without agitation; treating cancer | SYNTHON BV (NL) | 2008-07-10 | — | — | US | disclosed |
| US-20080167327-A1 | Crystalline, formed by crystallizing from an aqueous solution without agitation; treating cancer | SYNTHON BV (NL) | 2008-07-10 | — | — | US | disclosed |
| WO-2008049645-A2 | HYDRATES OF ERLOTINIB HYDROCHLORIDE | SYNTHON B.V. (NL) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008049645-A2 | HYDRATES OF ERLOTINIB HYDROCHLORIDE | SYNTHON B.V. (NL) | 2008-05-02 | — | — | WO | disclosed |
| CN-101016266-A | Novel amorphous form of erlotinib hydrochloride and its solid amorphous dispersion | MAI DE LTD (CN) | 2007-08-15 | — | — | CN | disclosed |
| US-20060154941-A1 | Novel amorphous form of erlotinib hydrochloride and its solid amorphous dispersion | MAI DE LTD. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167327-A1 | Crystalline, formed by crystallizing from an aqueous solution without agitation; treating cancer | TP53, KRAS, HRAS | EGFR 6/4885ERBB2 91/4885GAK 316/4885 |
| US-20060154941-A1 | Novel amorphous form of erlotinib hydrochloride and its solid amorphous dispersion | EGFR, EPS15, KRAS | EGFR 1/4885ERBB2 4/4885GAK 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.